Future perspectives for mTOR inhibitors in renal cell cancer treatment
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Future perspectives for mTOR inhibitors in renal cell cancer treatment
Authors
Keywords
-
Journal
Future Oncology
Volume 11, Issue 5, Pages 801-817
Publisher
Future Medicine Ltd
Online
2015-03-11
DOI
10.2217/fon.14.303
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Raloxifene and Antiestrogenic Gonadorelin Inhibits Intestinal Tumorigenesis by Modulating Immune Cells and Decreasing Stem-like Cells
- (2014) N. B. Janakiram et al. Cancer Prevention Research
- Melatonin Inhibits mTOR-Dependent Autophagy during Liver Ischemia/Reperfusion
- (2014) Jung-Woo Kang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States
- (2014) James E. Signorovitch et al. CURRENT MEDICAL RESEARCH AND OPINION
- A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer
- (2014) Thomas Powles et al. EUROPEAN JOURNAL OF CANCER
- Enhanced autophagy blocks angiogenesis via degradation of gastrin-releasing peptide in neuroblastoma cells
- (2013) Kwang Woon Kim et al. Autophagy
- Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment
- (2013) Elahu G. Sustarsic et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro
- (2013) Thomas M Cardillo et al. BMC CANCER
- Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
- (2013) Jun Guo et al. BMC CANCER
- Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells
- (2013) V Martín et al. BRITISH JOURNAL OF CANCER
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
- (2013) Ana M. Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium
- (2013) John D. Hainsworth et al. CANCER INVESTIGATION
- Hypoxia-induced autophagy in endothelial cells: a double-edged sword in the progression of infantile haemangioma?
- (2013) Gang Chen et al. CARDIOVASCULAR RESEARCH
- A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma
- (2013) Lauren C. Harshman et al. Clinical Genitourinary Cancer
- Are Tyrosine Kinase Inhibitors Still Active in Patients With Metastatic Renal Cell Carcinoma Previously Treated With a Tyrosine Kinase Inhibitor and Everolimus? Experience of 36 Patients Treated in France in the RECORD-1 Trial
- (2013) Aurore Blesius et al. Clinical Genitourinary Cancer
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptional and post-translational regulation of Bim controls apoptosis in melatonin-treated human renal cancer Caki cells
- (2013) Eun Jung Park et al. JOURNAL OF PINEAL RESEARCH
- Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma
- (2013) Yanhui Zhang et al. JOURNAL OF SURGICAL ONCOLOGY
- PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation
- (2013) Roberto Gedaly et al. JOURNAL OF SURGICAL RESEARCH
- Autophagy mediates paracrine regulation of vascular endothelial cells
- (2013) Kwang Woon Kim et al. LABORATORY INVESTIGATION
- Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors
- (2013) Yan-Na Liu et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy
- (2013) Agnes Maj-Hes et al. ONCOLOGY
- Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study
- (2013) Lothar Bergmann et al. ONKOLOGIE
- A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
- (2013) Hao Zhang et al. PLoS One
- Estrogen Inhibits Renal Cell Carcinoma Cell Progression through Estrogen Receptor-β Activation
- (2013) Cheng-Ping Yu et al. PLoS One
- Cancer-related networks: A help to understand, predict and change malignant transformation
- (2013) Peter Csermely et al. SEMINARS IN CANCER BIOLOGY
- Complex regulation of autophagy in cancer – Integrated approaches to discover the networks that hold a double-edged sword
- (2013) János Kubisch et al. SEMINARS IN CANCER BIOLOGY
- Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study
- (2013) Yan Liu et al. TUMOR BIOLOGY
- Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
- (2012) Y. Koh et al. ANNALS OF ONCOLOGY
- β-Elemene Induces Apoptosis in Human Renal-cell Carcinoma 786-0 Cells through Inhibition of MAPK/ERK and PI3K/Akt/mTOR Signalling Pathways
- (2012) Yun-Hong Zhan et al. Asian Pacific Journal of Cancer Prevention
- Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial
- (2012) Andrew Stein et al. BMC CANCER
- Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
- (2012) S Bracarda et al. BRITISH JOURNAL OF CANCER
- Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions
- (2012) Youn-Sang Jung et al. CELL CYCLE
- Glucocorticoids Modulate the mTOR Pathway in the Hippocampus: Differential Effects Depending on Stress History
- (2012) J. Annelies E. Polman et al. ENDOCRINOLOGY
- Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study
- (2012) Stéphane Oudard et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial
- (2012) Camillo Porta et al. EUROPEAN UROLOGY
- Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model
- (2012) Kil-Jung Kim et al. JOURNAL OF PINEAL RESEARCH
- Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database
- (2012) Alexandr Poprach et al. MEDICAL ONCOLOGY
- ERα, microRNAs, and the epithelial–mesenchymal transition in breast cancer
- (2012) Irene K. Guttilla et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program
- (2012) Alfonsus J.M. van den Eertwegh et al. UROLOGY
- Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
- (2011) D. Y. Heng et al. ANNALS OF ONCOLOGY
- Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
- (2011) V Grünwald et al. BRITISH JOURNAL OF CANCER
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
- (2011) Ana M. Molina et al. CANCER
- A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
- (2011) Andrea L. Harzstark et al. CANCER
- GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells
- (2011) Agnieszka Siejka et al. CELL CYCLE
- Phase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer
- (2011) Robert J. Amato et al. Clinical Genitourinary Cancer
- Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review
- (2011) Camillo Porta et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
- (2011) Viktor Grünwald et al. EUROPEAN JOURNAL OF CANCER
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
- (2011) E. Calvo et al. EUROPEAN JOURNAL OF CANCER
- Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase Inhibitors
- (2011) Jonas Busch et al. EUROPEAN UROLOGY
- Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region
- (2011) Eduard Vrdoljak et al. EXPERT OPINION ON PHARMACOTHERAPY
- Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study
- (2011) Evgeny Yakirevich et al. HUMAN PATHOLOGY
- The Mechanism of Insulin-stimulated 4E-BP Protein Binding to Mammalian Target of Rapamycin (mTOR) Complex 1 and Its Contribution to mTOR Complex 1 Signaling
- (2011) Joseph Rapley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Differentiation Therapy: Targeting Human Renal Cancer Stem Cells with Interleukin 15
- (2011) Sandy Azzi et al. JNCI-Journal of the National Cancer Institute
- Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
- (2011) J. L. Beaumont et al. ONCOLOGIST
- Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
- (2010) Dorothy A. White et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Hypothyroidism in patients with renal cell carcinoma
- (2010) Manuela Schmidinger et al. CANCER
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
- (2010) R. Quek et al. CLINICAL CANCER RESEARCH
- Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens
- (2010) Kristen M. Smith et al. EMBO Molecular Medicine
- Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
- (2010) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1
- (2010) T. Tsukamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
- (2010) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- The genetic basis of kidney cancer: a metabolic disease
- (2010) W. Marston Linehan et al. Nature Reviews Urology
- Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy
- (2010) Michael M. Vickers et al. UROLOGY
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth
- (2009) Virginie Kinet et al. CANCER LETTERS
- Expression of the K303R Estrogen Receptor- Breast Cancer Mutation Induces Resistance to an Aromatase Inhibitor via Addiction to the PI3K/Akt Kinase Pathway
- (2009) I. Barone et al. CANCER RESEARCH
- Differential Destruction of Stem Cells: Implications for Targeted Cancer Stem Cell Therapy
- (2009) M. E. Sehl et al. CANCER RESEARCH
- Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma
- (2009) Camillo Porta et al. CANCER TREATMENT REVIEWS
- A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma
- (2009) Christopher W. Ryan et al. INVESTIGATIONAL NEW DRUGS
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Systems approaches and algorithms for discovery of combinatorial therapies
- (2009) Jacob D. Feala et al. Wiley Interdisciplinary Reviews-Systems Biology and Medicine
- VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
- (2009) C. Lance Cowey et al. Current Oncology Reports
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Hypoxia-Associated Factor, a Novel E3-Ubiquitin Ligase, Binds and Ubiquitinates Hypoxia-Inducible Factor 1 , Leading to Its Oxygen-Independent Degradation
- (2008) M. Y. Koh et al. MOLECULAR AND CELLULAR BIOLOGY
- Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.
- (2008) Jorge A. Garcia et al. MOLECULAR CANCER THERAPEUTICS
- Models from experiments: combinatorial drug perturbations of cancer cells
- (2008) Sven Nelander et al. Molecular Systems Biology
- Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer
- (2007) Andrew V Schally et al. Nature clinical practice. Endocrinology & metabolism
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search